Navigating hope: study tests whether patient guides boost trial enrollment for cancer patients

NCT ID NCT06138067

Recruiting now Knowledge-focused Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two levels of patient navigation—high-intensity versus low-intensity—to see which helps more people with prostate or kidney cancer enroll in clinical trials. About 90 participants will be randomly assigned to receive either extra support from a patient navigator or standard materials. The goal is to find better ways to connect patients with potential new treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient navigation program
What this could lead to: If successful, this could show that extra support helps more cancer patients join clinical trials, potentially improving access to new treatments.
What could go wrong: This is a small pilot study with only 90 participants, so results may not apply broadly. It tests a support program, not a treatment, so it won't directly cure or control cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER PROSTATE CANCER

Contacts and locations

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21205, United States
Wellspan
NOT_YET_RECRUITING

Chambersburg, Pennsylvania, 17201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.